<div id="readability-page-1"><h3>Easter Sale - 70% Off TipRanks</h3><ul><li>Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions </li><li> Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks </li></ul>An announcement from TransThera Sciences (Nanjing). Inc. ( (HK:2617) ) is now available. TransThera Sciences (Nanjing), Inc. plans to adopt an H Share Award Scheme, enabling the grant of share-based awards funded through treasury shares, newly issued H shares, or existing H shares to eligible participants including employees, related entities and service providers. The initiative, which requires shareholder approval at an upcoming extraordinary general meeting and listing approval for any new shares, is designed to formalize equity incentives and may strengthen the company’s talent retention and alignment of stakeholder interests, while signaling a more mature capital management approach in line with Hong Kong listing rules. The board is also seeking authorization for a designated Scheme Administrator to handle all operational and documentation matters related to implementing the H Share Award Scheme, streamlining administration once the plan is approved. The company will issue a circular with further details and has urged shareholders and potential investors to exercise caution when trading its securities until the scheme’s adoption and related approvals are confirmed. More about TransThera Sciences (Nanjing). Inc. TransThera Sciences (Nanjing), Inc. is a joint stock company incorporated in the People’s Republic of China with limited liability, whose H shares are listed on the Hong Kong Stock Exchange under stock code 2617. The company operates in the biopharmaceutical sector, focusing on developing and commercializing innovative therapies and targeting global capital markets through its Hong Kong listing. Average Trading Volume: 2,501,105 Technical Sentiment Signal: Strong Sell Current Market Cap: HK$21.29B Learn more about 2617 stock on TipRanks’ Stock Analysis page.</div>

520690

513120

159748

159316

513700

02617

520500

520880

159506

159570

TransThera Sciences (Nanjing), Inc. plans to implement an H Share Award Scheme to enhance equity incentives for employees and service providers. This initiative requires shareholder approval and aims to improve talent retention and align stakeholder interests. The company will appoint a Scheme Administrator for operational matters and will issue a circular with more details. Shareholders are advised to exercise caution until the scheme is approved. TransThera Sciences is listed on the Hong Kong Stock Exchange under stock code 2617, focusing on biopharmaceutical innovations.

Tip Ranks

Bosera Hang Seng SCHK Innovative Drug Select ETF

GF CSI HK Innovative Drugs Industry ETF(QDII)

Fullgoal CSI Hugangshen Innovative Drugs Industry ETF

E Fund Hang Seng SCHK Innovative Drug ETF

Penghua CSI HK Connect Health Care Composite ETF

TRANSTHERA-B

Huatai-PB Hang Seng Innovative Drugs Industry ETF(QDII)

Hwabao WP Hang Seng SCHK Innovative Drug Select ETF

Fullgoal Hang Seng SCHK Innovative Drug & Healthcare ETF

China Universal CNI HK Connect Innovative Drugs Industry ETF

TransThera Sciences Proposes New H Share Award Scheme to Boost Equity Incentives